75-00-3

Applied Filters:

Keyword:'75-00-3'

Showing 1-16 of 16 results for "75-00-3" within Papers

Improved method for the extraction and chromatographic analysis on a fused-core column of ellagitannins found in oak-aged wine.

María Navarro et al.

Food chemistry, 226, 23-31 (2017-03-04)

A new method for the analysis of ellagitannins observed in oak-aged wine is proposed, exhibiting interesting advantages with regard to previously reported analytical methods. The necessary extraction of ellagitannins from wine was simplified to a single step of solid phase

The allele frequencies of HPA 1-16 determined by PCR-SSP in Chinese Cantonese donors.

Y-M Nie et al.

Transfusion medicine (Oxford, England), 20(6), 376-382 (2010-07-30)

Typing of human platelet antigens (HPA) has proven to be useful in some clinical situations related to platelet alloimmunization. The objective of this study was to investigate HPA 1-16 and to determine genotype and allele frequencies by polymerase chain reaction-sequence

Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.

Ivan Goldberg et al.

Journal of glaucoma, 21(1), 55-59 (2010-11-05)

To compare the efficacy of brinzolamide versus placebo when added to travoprost/timolol fixed combination (TTFC) in uncontrolled patients. This was a prospective, double-masked, randomized, placebo-controlled, parallel comparison of ocular hypertensive or primary open-angle glaucoma patients. Patients treated with a prostaglandin-based

The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma Patients.

Pelin Özyol et al.

Journal of glaucoma, 25(3), e145-e149 (2014-12-11)

To investigate the effect of nepafenac on intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients treated with prostaglandin (PG) analogs. This prospective clinical study included 35 patients who had been receiving latanoprost (n=12), travoprost (n=12), or bimatoprost (n=11) for

Anatomical Suitability of the Aortic Arch Arteries for a 3-Inner-Branch Arch Endograft.

Konstantinos Spanos et al.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 28(1), 14-19 (2020-09-02)

To analyze aortic arch anatomy of patients who were already treated with a 2-inner-branch arch endograft (2-IBAE) in order to assess the anatomical suitability of the supra-aortic arteries as target vessels for a 3-IBAE. Three different configurations of the Cook

Dietary antioxidants and periodontal disease in community-based older Japanese: a 2-year follow-up study.

Masanori Iwasaki et al.

Public health nutrition, 16(2), 330-338 (2012-05-23)

To investigate the longitudinal relationship between the intake of dietary antioxidants and periodontal disease in community-dwelling older Japanese. A retrospective cohort study, with a follow-up of 2 years (2003-2005). Intakes of dietary antioxidants (vitamin C, vitamin E, α-carotene and β-carotene)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Rachel S Kerr et al.

The Lancet. Oncology, 17(11), 1543-1557 (2016-09-24)

Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. For the open-label, randomised, controlled QUASAR 2 trial, which was

Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases.

N Inoue et al.

Clinical and experimental immunology, 163(3), 318-323 (2011-01-18)

To clarify the association of genetic producibility of interleukin (IL)-5, IL-6 and IL-13, which are secreted by T helper type 2 (Th2), with the development and prognosis of autoimmune thyroid disease (AITD), we genotyped IL5-746C/T, IL6-572C/G and IL13-1112C/T polymorphisms, which

Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial.

Matthew D Campbell et al.

PloS one, 9(5), e97143-e97143 (2014-05-27)

To examine the metabolic, gluco-regulatory-hormonal and inflammatory cytokine responses to large reductions in rapid-acting insulin dose administered prandially before and after intensive running exercise in male type 1 diabetes patients. This was a single centre, randomised, controlled open label study.

Sleep deprivation aggravates median nerve injury-induced neuropathic pain and enhances microglial activation by suppressing melatonin secretion.

Chun-Ta Huang et al.

Sleep, 37(9), 1513-1523 (2014-08-22)

Sleep deprivation is common in patients with neuropathic pain, but the effect of sleep deprivation on pathological pain remains uncertain. This study investigated whether sleep deprivation aggravates neuropathic symptoms and enhances microglial activation in the cuneate nucleus (CN) in a

Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.

Helena W Rodbard et al.

The lancet. Diabetes & endocrinology, 2(1), 30-37 (2014-03-14)

We compared stepwise addition of bolus insulin with a full basal-bolus regimen in patients with type 2 diabetes inadequately controlled on basal insulin plus oral antidiabetic drugs. The FullSTEP study was a phase 4, 32-week, randomised, open-label, two-arm, parallel-group, multinational

Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.

Alex Iranzo et al.

The Lancet. Neurology, 10(9), 797-805 (2011-08-02)

Serial dopamine transporter (DAT) imaging in patients with Parkinson's disease (PD) and other synucleinopathies shows progressive nigrostriatal dopaminergic dysfunction. Because idiopathic rapid-eye-movement (REM) sleep behaviour disorder (IRBD) can precede the classic symptoms of PD and other synucleinopathies, we postulated that

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Daniel P Petrylak et al.

The Lancet. Oncology, 16(4), 417-425 (2015-03-07)

Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

Annemiek Broyl et al.

The Lancet. Oncology, 11(11), 1057-1065 (2010-09-25)

Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two or three treatment

Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study.

Elise Cuyvers et al.

The Lancet. Neurology, 14(8), 814-822 (2015-07-05)

ABCA7 was identified as a risk gene for Alzheimer's disease in genome-wide association studies (GWAS). It was one of the genes most strongly associated with risk of Alzheimer's disease in a Belgian cohort. Using targeted resequencing, we investigated ABCA7 in

Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.

Katharina Fleischhauer et al.

The Lancet. Oncology, 13(4), 366-374 (2012-02-22)

The risks after unrelated-donor haemopoietic-cell transplantation with matched HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 alleles between donor and recipient (10/10 matched) can be decreased by selection of unrelated donors who also match for HLA-DPB1; however, such donors are difficult to find.

Page 1 of 1